Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus GANCICLOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus GANCICLOVIR.
ADEFOVIR DIPIVOXIL vs GANCICLOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
10 mg orally once daily on an empty stomach.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Clinical Note
moderateGanciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateTerminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for CrCl <70 mL/min
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Category C
Category D/X
Antiviral
Antiviral
Valganciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Valganciclovir."